Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.
Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. H...
